Each row is one molecule. Most advanced phase is the highest phase of any registered trial. Trials counts every trial registered on ClinicalTrials.gov that involves the molecule, with the number still active in brackets. Countries is the number of countries with at least one trial site. Choose your country to see only the molecules with a site there.
No tracked molecule has a trial site in this country.
| Molecule | Most advanced phase | Trials (active) | Countries with trial sites | Next milestonePrimary completion expected |
|---|---|---|---|---|
| RetatrutideEli Lilly | Phase 3 | 33 (11 active) | 38 | October 2026 NCT06297603 |
| OrforglipronEli Lilly | Phase 4 | 53 (21 active) | 44 | September 2029 NCT07739537 |
| CagriSema (cagrilintide + semaglutide)Novo Nordisk | Phase 3 | 44 (18 active) | 44 | March 2027 NCT07011667 |
| SurvodutideBoehringer Ingelheim | Phase 3 | 29 (11 active) | 46 | January 2028 NCT07754461 |
| MariTide (maridebart cafraglutide)Amgen | Phase 3 | 30 (17 active) | 36 | January 2027 NCT06858839 |
| AmycretinNovo Nordisk | Phase 3 | 23 (14 active) | 34 | June 2028 NCT07503210 |
| MazdutideInnovent / Eli Lilly | Phase 4 | 45 (25 active) | 5 | December 2027 NCT07657676 |
| PemvidutideAltimmune | Phase 3 | 16 (2 active) | 3 | December 2028 NCT07795164 |
| TirzepatideEli Lilly | Phase 4 | 298 (197 active) | 53 | December 2026 NCT06721507 |
| SemaglutideNovo Nordisk | Phase 4 | 782 (363 active) | 69 | October 2026 NCT05119179 |
| TesamorelinTheratechnologies | Phase 4 | 24 (3 active) | 7 | |
| Bremelanotide (PT-141)Palatin | Phase 4 | 10 (1 active) | 4 | |
| BPC-157 | Phase 2 | 4 (2 active) | 3 | February 2027 NCT07437547 |
| Thymosin beta-4 (TB-500) | Phase 3 | 18 (3 active) | 5 | |
| GHK-Cu (copper peptide) | Phase 4 | 3 (2 active) | 3 | |
| Elamipretide (SS-31)Stealth BioTherapeutics | Phase 4 | 21 (3 active) | 19 | September 2029 NCT07531251 |
Counts include every registered trial involving the molecule, including trials where it is a comparator. Dates are the sponsors' own estimates.
How to read this table
Method
The data comes from the public ClinicalTrials.gov API and is refreshed once a day. A trial is counted when the molecule appears in its interventions, so trials that use it as a comparator are included. The next milestone is the earliest expected primary completion date among the active trials at the most advanced phase: it is the sponsor's estimate, not a promise of results or approval.
What this table does not tell you
A trial site in a country does not mean the drug is available there. Only an approval by that country's medicines agency does. Research products sold online under the same name are not the molecules tested in these trials. This page is information only and is not medical advice.
Frequently asked questions
What does phase 3 mean?
Phase 3 trials test a treatment in large groups of patients, often thousands, to confirm its effect and safety before a company asks for approval.
Does a trial in my country mean the drug is available there?
No. Trial sites recruit volunteers under strict conditions. A drug is available only after the national medicines agency approves it.
How often is the tracker updated?
Every day, from the ClinicalTrials.gov public database.
Why are BPC-157 and TB-500 in the list?
Because readers ask about them. The table shows how little human trial data exists for them compared with the GLP-1 molecules.